By Chris Hutching
Friday 21st March 2003
|Text too small?|
"Most stock valuations currently aren't out of whack and there's a greater than even chance that the biotech dealmaking engine might splutter back to life with a vengeance," he told the Commercialising Biotechnology Conference in Auckland this week.
"What we can reasonably expect is a wave of mergers and acquisitions to strengthen investor confidence in the sector," he said.
"Just in case some of you big spenders out there would like to take your wallets out and spend up large, some of the once-hot names now trading below cash value include Celera Genomics, Transkaryotic Therapies, Incyte Genomics, Sequenom and Curagen.
"Indeed, there was much market speculation only a couple of weeks ago when Wrightson snared just over 15% of Genesis at much below Genesis' cash value if the company was wound up today.
But the biggest recent news was the impending merger of Pfizer and Pharmacia Corp. "It effectively creates a new model for US drug companies."
No comments yet
Further Contract Win Strengthens Scott Technology’s Position In Mining Sector
China’s Assertiveness Is Becoming a Problem for Its Friends, Too
New Talisman - Chairman’s Address to AGM 2020 August 6, 2020
T&G reports its 2020 Interim Results
Gold price hits $2,000 for first time on Covid
TruScreen strengthens its market presence in central and eastern Europe
Refining NZ announces non-cash impairment
Ryman Healthcare COVID-19 update Victoria
Talisman Quarterly Activities Report to 30 June 2020
General Capital gives notice of Annual Meeting